Cover Image
市場調查報告書

胃癌的全球市場 (2016年)

Global Gastric Cancer Market Report: 2016 Edition

出版商 Koncept Analytics 商品編碼 358801
出版日期 內容資訊 英文 52 Pages
訂單完成後即時交付
價格
Back to Top
胃癌的全球市場 (2016年) Global Gastric Cancer Market Report: 2016 Edition
出版日期: 2016年05月31日 內容資訊: 英文 52 Pages
簡介

所謂胃癌是在胃的表皮和胃壁內部的淋巴節·淋巴管產生癌細胞,並增生、轉移的疾病。胃癌的原因至今尚未確定,但抽煙和鹽分攝取過量、肥胖、老齡化與胃癌有所關聯。此外感染幽門螺桿菌,併發胃癌的可能性也相當高。雖然至今胃癌的預後狀態都不佳,但半由早期診斷及活用標的療法,近年來已有大幅改善。有效的平台產品也在逐步開發、等待上市中,但標的療法的普及率低、癌症治療藥的醫療費給付額不足,都有妨礙市場成長的可能性。

本報告提供胃癌治療藥的市場相關分析,提供您疾病概要和主要的治療方法·治療藥,全球市場規模(發病數量·市場收益額等),主要地區詳細趨勢,主要的推動及阻礙市場要素,彙整現在正在開發的開發中產品與其上市預測,企業間競爭現況(企業規模比較等),主要企業簡介等調查評估。

第1章 市場概要

  • 簡介
  • 種類
  • 階段 (分期)
  • 原因與預防法
  • 診斷
    • 症狀
    • 醫療診斷
  • 治療選擇
    • 外科手術
    • 化療
    • 放射治療
    • 標靶治療

第2章 全球市場

  • 全球胃癌市場:患病者別
  • 全球晚期胃癌市場:以金額為準

第3章 各地區市場

  • 美國
    • 胃癌市場:患病人數
    • Her 2+胃癌市場:患病人數
    • 第三期胃癌市場:患病人數
    • 進行性胃癌市場:患病人數
    • 進行性胃癌市場:以金額為準
    • 轉移胃癌市場:患病人數
  • EU (歐洲聯盟) 各國
    • Her 2+胃癌市場:患病人數
    • 第三期胃癌市場:患病人數
    • 轉移胃癌市場:患病人數
  • EU主要5個國家
    • 胃癌市場:患病人數
    • 進行性胃癌市場:患病人數
    • 進行性胃癌市場:以金額為準
  • 日本
    • 胃癌市場:患病人數
    • 進行性胃癌市場:患病人數
    • 進行性胃癌市場:以金額為準

第4章 市場動態

  • 成長推動因素
    • 癌症標靶治療支出額的擴大
    • 腫瘤藥支出額的擴大
    • 老年人口的增加
    • 肥胖人口的增加
    • 全球男性人口的增加
    • 香煙消費量的增加
  • 市場趨勢
    • 現在正在開發的組合型標靶治療
    • 現在正在開發的標靶藥物
    • 分子標靶治療的轉變
    • 幽門螺桿菌的根絕
  • 課題
    • 新標靶治療的普及率低
    • 對癌症治療藥的醫療費給付額不足

第5章 競爭環境

  • 全球癌症市場
    • 主要癌症治療藥的收益額比較
    • 未來性聯合治療的上市預測
  • 全球胃癌市場
    • 主要企業比較:收益額
    • 主要企業比較:收益額成長率
    • 現在臨床實驗中的胃癌用產品

第6章 企業簡介

  • Roche Holdings AG
    • 產業概要
    • 財務狀況
    • 產業策略
  • Bristol Myers Squibb
  • Merck & Co. Inc.
  • AstraZeneca Plc.

圖表一覽

目錄

Cancer is a condition where an error or mutation in the cell's DNA occurs, causing it to grow at a rapid rate. A cancer cell continues living while a normal cell would die, thus, accumulating to form a tumor that can break off and spread throughout the body. Gastric cancer is when such a condition occurs in the stomach and has the tendency to grow through the wall of the stomach to invade nearby organs including lymph nodes and lymph vessels. There are four types of cancers of the stomach namely, Adenocarcinoma, Lymphoma, Gastrointestinal stromal tumor (GIST), Carcinoid tumor and others such as squamous cell carcinoma, small cell carcinoma, and leiomyosarcomat that can start in the stomach, but are very rare.

The causes of stomach cancer are rather unclear in medical study; however, there is a strong correlation between a diet high in smoked, salted and pickled foods, obesity and ageing. People with Helicobacter infections are also highly prone to gastric cancer. Symptoms of gastric cancer may include, fatigue, feeling bloated after eating, severe heartburn and indigestion, stomach pain, persistent and unexplained vomiting and nausea, unintentional weight loss, belching, anemia, and persistent ulcer. Its medical diagnosis techniques involve upper endoscopy, imaging tests and exploratory surgery. Treatment options include surgery, chemotherapy, radiotherapy and targeted therapy.

Global gastric cancer market is conspicuous by poor prognosis, because of the indolent nature of the disease. However, better diagnostic technology and shifting treatment market from chemotherapy to targeted therapies is expected to warrant positive growth in the years ahead. Rising oncology drug spending, ageing population, increasing obese population and rising global male population are expected to drive this growth. Certain trends in the global gastric cancer market include, a healthy pipeline of combinations targeted therapies, shifting focus towards molecular targeted therapies, and keen interest in eradication H. Pylori infection across the globe. The market is however, afflicted by certain challenges like low penetration of new targeted therapies and lack of reimbursement of cancer drugs.

The report provides an overview of the entire market through global and regional analysis. Prevalence and market value of gastric cancer across the globe and that of its various types and stages including advanced, her2 positive, stage III and metastatic gastric cancer have been analyzed.

Table of Contents

1. Market Overview

  • 1.1. Introduction
  • 1.2. Types
  • 1.3. Stages
  • 1.4. Causes & Prevention
  • 1.5. Diagnosis
    • 1.5.1. Symptoms
    • 1.5.2. Medical Diagnosis
  • 1.6. Treatment Options
    • 1.6.1. Surgery
    • 1.6.2. Chemotherapy
    • 1.6.3. Radiotherapy
    • 1.6.4. Targeted Therapy

2. Global Market

  • 2.1. Global Gastric Cancer Market by Prevalence
  • 2.2. Global Advanced Gastric Cancer Market by Value

3. Regional Markets

  • 3.1. The U.S.
    • 3.1.1. The U.S. Gastric Cancer Market by Prevalence
    • 3.1.2. The U.S. Her 2+ Gastric Cancer Prevalence
    • 3.1.3. The U.S. Stage III Gastric Cancer Prevalence
    • 3.1.4. The U.S. Advanced Gastric Cancer Market by Prevalence
    • 3.1.5. The U.S. Advanced Gastric Cancer Market by Value
    • 3.1.6. The U.S. Metastatic Gastric Cancer Prevalence
  • 3.2. The European Union
    • 3.2.1. The EU Her 2+ Gastric Cancer Prevalence
    • 3.2.2. The EU Stage III Gastric Cancer Prevalence
    • 3.2.3. The EU Metastatic Gastric Cancer Prevalence
  • 3.3. The EU5
    • 3.3.1. The EU5 Gastric Cancer Market by Prevalence
    • 3.3.2. The EU5 Advanced Gastric Cancer Market by Prevalence
    • 3.3.3. The EU5 Advanced Gastric Cancer Market by Value
  • 3.4. Japan
    • 3.4.1. Japan Gastric Cancer Market by Prevalence
    • 3.4.2. Japan Advanced Gastric Cancer Market by Prevalence
    • 3.4.3. Japan Advanced Gastric Cancer Market by Value

4. Market Dynamics

  • 4.1. Growth Drivers
    • 4.1.1. Rising Spending on Targeted Cancer Therapies
    • 4.1.2. Rising Oncology Drug Spending
    • 4.1.3. Rising Ageing Population
    • 4.1.4. Increasing Obese Population
    • 4.1.5. Rising Global Male Population
    • 4.1.6. Rising Cigarette Consumption
  • 4.2. Trends
    • 4.2.1. Combinations Targeted Therapies under Development
    • 4.2.2. Targeted Agents in Development by Pathways
    • 4.2.3. Shifting Focus towards Molecular Targeted Therapies
    • 4.2.4. H. Pylori Eradication
  • 4.3. Challenges
    • 4.3.1. Low Penetration of New Targeted Therapies
    • 4.3.2. Lack of Reimbursement of Cancer Drugs

5. Competitive Landscape

  • 5.1. Global Cancer Market
    • 5.1.1. Top Cancer Drugs Revenue Comparison
    • 5.1.2. Potential Combination Therapy Launches
  • 5.2. Global Gastric Cancer Market
    • 5.2.1. Top Companies by Revenue
    • 5.2.2. Top Companies by Revenue Growth
    • 5.2.3. Gastric Cancer Products under Clinical Trial

6. Company Profiles

  • 6.1. Roche Holdings AG
    • 6.1.1. Business Overview
    • 6.1.2. Financial Overview
    • 6.1.3. Business Strategies
  • 6.2. Bristol Myers Squibb
    • 6.2.1. Business Overview
    • 6.2.2. Financial Overview
    • 6.2.3. Business Strategies
  • 6.3. Merck & Co. Inc.
    • 6.3.1. Business Overview
    • 6.3.2. Financial Overview
    • 6.3.3. Business Strategies
  • 6.4. AstraZeneca Plc.
    • 6.4.1. Business Overview
    • 6.4.2. Financial Overview
    • 6.4.3. Business Strategies

List of Charts

  • Different Types of Gastric Cancer
  • Global Gastric Cancer Market by Prevalence (2015-2020E)
  • Global Advanced Gastric Cancer Market by Value (2015-2020E)
  • The U.S. Gastric Cancer Market by Prevalence (2015-2020E)
  • Prevalence of Her 2+ Gastric Cancer in the U.S. (2015-2020E)
  • Prevalence of Stage III Gastric Cancer in the U.S. (2015-2020E)
  • The U.S. Advanced Gastric Cancer Market by Prevalence (2015-2020E)
  • The U.S. Advanced Gastric Cancer Market by Value (2015-2020E)
  • Prevalence of Metastatic Gastric Cancer in the U.S. (2015-2020E)
  • Prevalence of Her2+ Gastric Cancer in the EU (2015-2020E)
  • Prevalence of Stage III Gastric Cancer in the EU (2015-2020E)
  • Prevalence of Metastatic Gastric Cancer in the EU (2015-2020E)
  • The EU5 Gastric Cancer Market by Prevalence (2015-2020E)
  • The EU5 Advanced Gastric Cancer Market by Prevalence (2015-2020E)
  • The EU5 Advanced Gastric Cancer Market by Value (2015-2020E)
  • Japan Gastric Cancer Market by Prevalence (2015E-2020E)
  • Japan Advanced Gastric Cancer by Prevalence (2015-2020E)
  • Japan Advanced Gastric Cancer Market by Value (2015-2020E)
  • Global Targeted Therapies Spending (2010-2015E)
  • Global Oncology Drug Spending by Region (2010-2015E)
  • Global Population Over 50 Years of Age (2010-2015E)
  • Global Obese Population (2010-2015E)
  • Global Male Population (2010-2015E)
  • Global Cigarettes Consumption (1910-2014)
  • Combination Regimen Launches in Oncology (2014-2020E)
  • Pipeline of Targeted Agents in Development by Pathways (2015)
  • Penetration of New Targeted Therapies by Country (2015)
  • Cancer Drugs Reimbursement Status by Country (2015E)
  • Potential Combination Therapy Launches by Company (2021E)
  • Gastric Cancer - Top Companies Revenue Comparison (2015)
  • Gastric Cancer - Revenue Growth Comparison by Company (2015)
  • Roche Holdings AG Revenue by Segment (2015)
  • Roche Holdings AG Revenue and Net Income (2011-2015)
  • Bristol Myers Revenue by Region (2015)
  • BMY Revenue and Net Income (2011-2015)
  • Merck & Co. Inc. Revenue by Segment (2015)
  • Merck & Co. Inc. Revenue and Net Income (2011-2015)
  • AstraZeneca Revenue by Region (2015)
  • AstraZeneca Revenue and Net Income (2011-2015)

List of Tables

  • Types of Targeted Therapies
  • Top Cancer Drugs by Revenue (2015)
  • Gastric Cancer Pre-Treated Clinical Trials Comparison
  • Gastric Cancer Treatment Naive Clinical Trials
Back to Top